GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects.

Article Details

Citation

Copy to clipboard

Krogsgaard-Larsen P, Frolund B, Frydenvang K

GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects.

Curr Pharm Des. 2000 Aug;6(12):1193-209.

PubMed ID

10903390 [ View in PubMed

]

Abstract

In the mid seventies a drug design programme using the Amanita muscaria constituent muscimol (7) as a lead structure, led to the design of guvacine (23) and (R)-nipecotic acid (24) as specific GABA uptake inhibitors and the isomeric compounds isoguvacine (10) and isonipecotic acid (11) as specific GABAA receptor agonists. The availability of these compounds made it possible to study the pharmacology of the GABA uptake systems and the GABAA receptors separately. Based on extensive cellular and molecular pharmacological studies using 23, 24, and a number of mono- and bicyclic analogues, it has been demonstrated that neuronal and glial GABA transport mechanisms have dissimilar substrate specificities. With GABA transport mechanisms as pharmacological targets, strategies for pharmacological interventions with the purpose of stimulating GABA neurotransmission seem to be (1) effective blockade of neuronal as well as glial GABA uptake in order to enhance the inhibitory effects of synaptically released GABA, or (2) selective blockade of glial GABA uptake in order to increase the amount of GABA taken up into, and subsequently released from, nerve terminals. The bicyclic compound (R)-N-Me-exo-THPO (17) has recently been reported as the most selective glial GABA uptake inhibitor so far known and may be a useful tool for further elucidation of the pharmacology of GABA transporters. In recent years, a variety of lipophilic analogues of the amino acids 23 and 24 have been developed, and one of these compounds, tiagabine (49) containing (R)-nipecotic acid (24) as the GABA transport carrier-recognizing structure element, is now marketed as an antiepileptic agent.

DrugBank Data that Cites this Article

Drugs

Guvacine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Guvacine	Sodium- and chloride-dependent GABA transporter 2	Protein	Humans	Unknown	Inhibitor	Details